Expression profile of maternal circulating microRNAs as non-invasive biomarkers for prenatal diagnosis of congenital heart defects - 09/12/18
pages | 8 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Expression profile of miRNAs in the serum of pregnant women with congenital heart defect fetuses were explored. |
• | First examined the maternal circulating miRNA expression in single ventricle and persistent truncus arteriosus. |
• | A panel consisting of four miRNAs showed excellent diagnostic ability for fetal congenital heart defects. |
• | Highlight the clinical potential of these miRNA as biomarkers for prenatal diagnosis of fetal congenital heart defects. |
Abstract |
Objective |
The discovery of cell free fetal microRNAs (miRNAs) in maternal circulation has opened up novel probabilities for non-invasive prenatal diagnosis. This study aims to investigate circulating miRNAs as potential biomarkers in the serum of pregnant women with congenital heart defect (CHD) fetuses.
Method |
A total of 110 pregnant women including 50 CHD cases and 60 healthy controls were included in this study. miRNA microarray followed by real-time PCR was used to explore miRNA expression. Receiver operating characteristic (ROC) curves were calculated to assess the diagnostic capability of miRNAs for fetal CHDs.
Results |
38 Serum miRNAs were revealed to be differentially expressed in the CHD group as compared to control group via microarray. Among these, nine down-regulated and three up-regulated miRNAs were validated by real-time PCR. Ten of these miRNAs were rapidly reduced in the normal maternal serum after delivery as compared to before delivery. In particular, we identified a biomarker panel consisting of four miRNAs (miR-142-5p, miR-1275, miR-4666a-3p and miR-3664-3p) capable of distinguishing CHDs from controls (area under the ROC curve (AUC), 0.920; p < 0.0001).
Conclusion |
The discovery of these dysregulated pregnancy-associated miRNAs in maternal serum may be potential biomarkers for non-invasive prenatal diagnosis of fetal CHDs.
Le texte complet de cet article est disponible en PDF.Keywords : Congenital heart defects, Prenatal diagnosis, MicroRNA, Biomarker, Serum
Plan
Vol 109
P. 823-830 - janvier 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?